DWA
VRNA

Dorsey Wright & Associates’s Verona Pharma VRNA Stock Holding History

Dorsey Wright & Associates’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-43,134
Closed -$4.08M – 170
2025
Q2 		$4.08M Sell
43,134
-27,537
-39% -$2.04M 0.97% 37
2025
Q1 		$4.49M Sell
70,671
-7,975
-10% -$477K 1.14% 28
2024
Q4 		$3.65M Sell
78,646
-1,548
-2% -$58.1K 0.87% 44
2024
Q3 		$2.31M Buy
+80,194
New +$1.97M 0.55% 84

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dorsey Wright & Associates's VRNA Position: Q3 2025 in Review

Dorsey Wright & Associates sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 43,134 shares — an estimated $4.08M sold.

Dorsey Wright & Associates first reported a position in VRNA in Q3 2024 and held it in 4 quarters. The position peaked at $4.49M in Q1 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Dorsey Wright & Associates reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Dorsey Wright & Associates sold 43,134 Verona Pharma shares in Q3 2025, an estimated $4.08M.
  • Dorsey Wright & Associates first reported a position in Verona Pharma in Q3 2024 and held it in 4 quarters.
  • Dorsey Wright & Associates's Verona Pharma position peaked at $4.49M in Q1 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Dorsey Wright & Associates's 13F filing for Q3 2025, filed 18 Nov 2025.